Nestle launches website for individuals on weight loss drugs
June 25 (Reuters) -Nestle's NESN.S health unit on Tuesday launched a web platform to provide nutritional support for individuals on weight loss programs, including those using GLP-1 medications.
Nestle Health Science said the website will address specific needs such as preserving lean muscle mass, supporting gut health, and offering personalized diet assistance.
WHY IT'S IMPORTANT
As more people use GLP-1 drugs for weight control, several telehealth companies have started offering services to support these individuals.
In June,Kroger Health, the division of the grocery chain Kroger K.N that operates pharmacies and clinics across the U.S., revamped its weight management program to offer patients access to medical treatments such as Wegovy, Zepbound and others.
Health and wellness platform Hims & Hers HIMS.N Health in May also addedcompounded versions of GLP-1 injections to its comprehensive weight loss portfolio
CONTEXT
GLP-1 medications have recently become popular and are in strong demand in the U.S. These drugs, including Novo Nordisk's NOVOb.CO Ozempic and Wegovy, were initially developed to treat type 2 diabetes but also help with weight loss by suppressing appetite and promoting fullness.
However, there have been intermittent shortages over the past year, with makers such as Novo Nordisk and Eli Lilly LLY.N, which makes Mounjaro racing to ramp up supply.
The growing use of these drugs has led experts to project annualglobal sales of about $150 billion by the early 2030s.
Reporting by Ananya Mariam Rajesh in Bengaluru; Editing by Tasim Zahid
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
